Back to top
more

Rigel Pharmaceuticals (RIGL)

(Delayed Data from NSDQ)

$15.08 USD

15.08
186,112

+0.58 (4.00%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks News

Company News for Apr 14, 2021

Companies in the news are: MFNC, NVCR, RIGL, VTVT

Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -10.00% and 0.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Rigel Pharmaceuticals (RIGL) Stock?

Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.

Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 4.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Rigel Announces Sponsored Mid-Stage Coronavirus Therapy Study

Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 23.08% and 12.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to Decline

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Rigel Pharmaceuticals (RIGL) Looks Good: Stock Adds 9.7% in Session

Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study

Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.

Rigel Pharmaceuticals (RIGL) Q1 Earnings Match Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 0.00% and -2.08%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Misses Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 9.09% and -2.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I

Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.

Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study

Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.

Rigel Gets Positive CHMP Review for Thrombocytopenia Drug

The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.

Sanghamitra Saha headshot

Pharma Sector Tops in October: Best ETFs & Stocks

Pharma sector wins in October, making these ETFs and stocks winners.

Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 36.36% and 28.19%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 14.29% and 12.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Bausch Health (BHC) in Q2 Earnings?

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.

Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Rigel Pharmaceuticals, Inc. (RIGL) has been struggling lately, but the selling pressure may be coming to an end soon.